Effect of arotinolol on left ventricular function in patients with idiopathic dilated cardiomyopathy

Chao-mei Fan1, Hong Yang, Yi-shi Li

  • 1Clinical Pharmacology Center, Cardiovascular Institute & Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing. Fred_Fan2004@yahoo.com.cn

Insights

Long-term arotinolol treatment significantly improved left ventricular function and was safe in patients with idiopathic dilated cardiomyopathy (IDCM). This beta-blocker therapy offers a promising option for managing this heart condition.

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Idiopathic dilated cardiomyopathy (IDCM) is a serious condition affecting heart muscle function.
  • Effective long-term management strategies for IDCM are crucial for improving patient outcomes.

Purpose of the Study:

  • To assess the efficacy and safety of prolonged arotinolol treatment in patients diagnosed with IDCM.
  • To evaluate the impact of arotinolol on left ventricular function over a 12-month period.

Main Methods:

  • Sixty-three IDCM patients received 12-month arotinolol therapy alongside standard congestive heart failure treatment.
  • Left ventricular function was evaluated using the New York Heart Association functional class and two-dimensional echocardiography.

Main Results:

  • Arotinolol treatment led to significant improvements in left ventricular systolic function.
  • Key indicators such as left ventricular end-systolic dimension and ejection fraction showed marked positive changes.
  • Left ventricular mass index also decreased, indicating potential reverse remodeling.

Conclusions:

  • Twelve-month arotinolol treatment demonstrated a favorable impact on left ventricular function in IDCM patients.
  • The study suggests arotinolol is a safe and well-tolerated therapeutic option for long-term use in this patient population.
Abstract

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...